Sciwind Biosciences has received marketing authorisation in its China homeland for its first-in-class cAMP-biased GLP-1 receptor agonist, ecnoglutide, for the long-term management of weight in adults with overweight or obesity. The drug, which employs a novel biased signalling mechanism designed to selectively activate the cAMP pathway, achieved an average weight reduction of 15.4% (15.1% when adjusted for placebo) over 48 weeks in a Chinese Phase III trial. Notably, 92.8% of participants achieved a clinically meaningful weight loss of 5% or more.

The approval is based on the positive SLIMMER Phase III trial. Beyond weight loss, the therapy demonstrated significant improvements in key cardiometabolic risk markers, including waist circumference, blood pressure, lipids, liver fat content and insulin resistance. Ecnoglutide was approved for type 2 diabetes (T2D) in China in January 2026, and this latest approval completes a strategic dual-indication launch in the metabolic disease sector.

PharmCube's NextBiopharm® database shows that last month Sciwind granted China commercialisation rights to Pfizer in a deal valued at USD 495 million. Click here to request a free trial for NextBiopharm®.